{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:46Z","timestamp":1789676206436,"version":"4.0.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/jcp.0b013e318203b405","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T05:39:24Z","timestamp":1293687564000},"page":"115-119","source":"Crossref","is-referenced-by-count":5,"title":["The Impact of Dosage of Sustained-Release Formulation on Valproate Clearance and Plasma Concentration in Psychiatric Patients"],"prefix":"10.1097","volume":"31","author":[{"given":"Tatta","family":"Sriboonruang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duangchit","family":"Panomvana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santichai","family":"Chamchitchun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orawan","family":"Silpakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-21-20210128","first-page":"14","article-title":"Valproic acid and sodium valproate approved for use in epilepsy.","volume":"8","year":"1978","journal-title":"FDA Drug Bull"},{"issue":"suppl 2","key":"R2-21-20210128","first-page":"5","article-title":"The history of valproate in clinical neuroscience.","volume":"37","author":"Henry","year":"2003","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"R3-21-20210128","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"R4-21-20210128","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1097\/00004714-200002001-00001","article-title":"Comprehensive review of the psychiatric uses of valproate.","volume":"20","author":"Davis","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 1","key":"R5-21-20210128","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1097\/00004714-199202001-00007","article-title":"Valproate in the treatment of bipolar disorder: literature review and clinical guidelines.","volume":"12","author":"McElroy","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/030079907X188116","article-title":"Valproate in the treatment of PTSD: systematic review and meta analysis.","volume":"23","author":"Adamou","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"R7-21-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17425250902911455","article-title":"A review of valproate in psychiatric practice.","volume":"5","author":"Haddad","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"R8-21-20210128","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt1977216736","article-title":"Pharmacokinetics and bioavailability of sodium valproate.","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"R9-21-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00007691-198403000-00005","article-title":"Pharmacokinetics of enteric-coated valproic acid.","volume":"6","author":"Albright","year":"1984","journal-title":"Ther Drug Monit"},{"issue":"5-6","key":"R10-21-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1440-1819.1995.tb01910.x","article-title":"Pharmacokinetics of slow-release preparations of sodium valproate.","volume":"49","author":"Yamatogi","year":"1995","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future.","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"issue":"2","key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197713020-00001","article-title":"Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.","volume":"13","author":"Pinder","year":"1977","journal-title":"Drugs"},{"issue":"6","key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","article-title":"Therapeutic monitoring of valproate in psychiatry: how far have we progressed?","volume":"29","author":"Fleming","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"R14-21-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.153.6.765","article-title":"Relation of serum valproate concentration to response in mania.","volume":"153","author":"Bowden","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"2","key":"R15-21-20210128","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003495-199447020-00008","article-title":"Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy.","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"suppl 2","key":"R18-21-20210128","first-page":"25","article-title":"Pharmacokinetics, drug interactions, and tolerability of valproate.","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/clpt.1980.192","article-title":"Valproic acid dosage and plasma protein binding and clearance.","volume":"28","author":"Bowdle","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"R21-21-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2710.1993.tb00612.x","article-title":"Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications.","volume":"18","author":"Gomez Bellver","year":"1993","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"R22-21-20210128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.jcp.0000088903.24613.2a","article-title":"Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly.","volume":"23","author":"Felix","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"R23-21-20210128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.wnf.0000154221.37887.73","article-title":"Psychotropic drug interactions with valproate.","volume":"28","author":"Fleming","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"R24-21-20210128","first-page":"A189","article-title":"Evaluation of the potential pharmacokinetic interaction between sodium valproate and the investigational antiepileptic drug talampanel.","volume":"64","author":"Gidal","year":"2005","journal-title":"Neurology"},{"key":"R25-21-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2710.2005.00671.x","article-title":"Valproate: a simple chemical with so much to offer.","volume":"30","author":"Peterson","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"R26-21-20210128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.jcp.0000168485.76397.5c","article-title":"Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy.","volume":"25","author":"Eyer","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"R27-21-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.1995.tb00651.x","article-title":"Relationship between valproic acid dosage, plasma-concentration and clearance in adult monotherapy patients with epilepsy.","volume":"20","author":"Gidal","year":"1995","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"R28-21-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF00314255","article-title":"Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.","volume":"235","author":"Herngren","year":"1988","journal-title":"J Neurol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0b013e318203b405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:47Z","timestamp":1786041947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201102000-00021"}},"subtitle":["Analysis Based on Routine Therapeutic Drug Monitoring Data"],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318203b405","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}